FAM8A1 Activators
FAM8A1 Activators primarily function by influencing upstream signaling networks that FAM8A1 is involved in, such as the RAS-MAPK and PI3K-Akt pathways. Epidermal Growth Factor (EGF) and Epigallocatechin Gallate (EGCG) are examples of such activators, with EGF capable of initiating signaling cascades through its interaction with EGFR, and EGCG modulating EGFR activity. Sorafenib, an inhibitor of multiple kinases, can similarly alter downstream signaling and enhance FAM8A1 activity. Dihydrotestosterone (DHT) and Estradiol, by binding to their respective receptors, can initiate signaling cascades that involve FAM8A1.
In the same vein, other FAM8A1 Activators like Cyclosporine A, Rapamycin, Forskolin, Staurosporine, H-89 dihydrochloride, GF109203X, and U0126 can influence FAM8A1 activity byaltering various signaling pathways. Cyclosporine A acts through the inhibition of calcineurin, which can lead to the enhancement of FAM8A1 activity by upregulating the PI3K-Akt pathway. Similarly, the mTOR inhibitor, Rapamycin, can also enhance the PI3K-Akt pathway, leading to an increase in FAM8A1 activity. Forskolin, by enhancing cAMP production, can affect PKA activity and cellular signaling, resulting in the upregulation of the PI3K-Akt pathway and subsequently, enhancement of FAM8A1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG inhibits EGFR, leading to altered signaling downstream. Inhibition of EGFR can cause a compensatory upregulation of the RAS-MAPK pathway that FAM8A1 is involved in, enhancing FAM8A1 activity. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $63.00 $182.00 | 8 | |
Estradiol binds to estrogen receptors and initiates signaling cascades that involve FAM8A1, such as the PI3K-Akt pathway, enhancing FAM8A1 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple kinases, altering signaling downstream. The altered signaling can lead to the upregulation of the RAS-MAPK pathway that FAM8A1 is involved in, enhancing FAM8A1 activity. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporine A inhibits calcineurin, leading to altered signaling downstream. Calcineurin inhibition can result in the upregulation of the PI3K-Akt pathway that FAM8A1 is involved in, enhancing FAM8A1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, leading to altered signaling downstream. mTOR inhibition can result in the upregulation of the PI3K-Akt pathway that FAM8A1 is involved in, enhancing FAM8A1 activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits protein kinases, altering signaling downstream. This altered signaling can lead to the upregulation of the PI3K-Akt pathway that FAM8A1 is involved in, enhancing FAM8A1 activity. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H-89 inhibits PKA, leading to altered signaling downstream. PKA inhibition can result in the upregulation of the PI3K-Akt pathway that FAM8A1 is involved in, enhancing FAM8A1 activity. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF109203X inhibits PKC, leading to altered signaling downstream. PKC inhibition can result in the upregulation of the PI3K-Akt pathway that FAM8A1 is involved in, enhancing FAM8A1 activity. | ||||||